DIAGNOS to Provide Retinal Image Analysis using its AI Technology to 20/20NOW

Diagnos (TSXV:ADK) announced a three year agreement to provide CARA (Computer Assisted Retina Analysis) to 20/20Now, a leading Ocular Telehealth provider in the United States.

Diagnos, a leader in early detection of health issues through the use of Artificial Intelligence (AI) said that 20/20NOW will use CARA to upload their retinal images and retrieve the results after analysis by algorithms which can detect anomalies.

As quoted in the press release:

Identifying diabetic retinopathy (“DR”) in its early stages, when it’s most treatable, is critical to prevent blindness and help at lowering health care costs.

“At DIAGNOS, we’re pleased to welcome an innovative company, 20/20NOW, as a new customer and business partner.  We also want to extend a warm welcome to their network of more than 60 customers located across the United States. We will exclusively provide rapid and early detection of DR to their customers in the optical space.  As 20/20NOW expands their network, we will provide them with fast and reliable detection of DR. As we introduce new healthcare applications, we will work with 20/20NOW to leverage their network and provide early detection of other illnesses to the benefit of their patients.” said Yves-Stephane Couture, Vice-President of Sales at DIAGNOS.

Telehealth industry veteran and 20/20NOW CEO, Chuck Scott, stated “Our mission at 20/20NOW is to expand access to comprehensive eye exams while also improving the standard of care, at a lower cost to our patients. Through the use of cutting-edge AI technology provided by DIAGNOS, our Ocular Telehealth eye exams represent a cost-effective tool to help solve one of the most pressing health care issue in our country today.”

Mr. Scott further stated “The opportunity exists to combine the use of AI and Ocular Telehealth to cost effectively screen and detect other critical health diseases beyond diabetic retinopathy. We believe there will be a vast array of ocular diseases that can be detected through AI and retinal screenings in the future. We look forward to partnering with DIAGNOS to bring these capabilities to market.”

Click here for the full text release.